Literature DB >> 32571931

Spatiotemporal dynamics of innate immune signaling via RIG-I-like receptors.

Katharina Esser-Nobis1, Lauren D Hatfield1, Michael Gale2.   

Abstract

RIG-I, MDA5, and LGP2 comprise the RIG-I-like receptors (RLRs). RIG-I and MDA5 are essential pathogen recognition receptors sensing viral infections while LGP2 has been described as both RLR cofactor and negative regulator. After sensing and binding to viral RNA, including double-stranded RNA (dsRNA), RIG-I and MDA5 undergo cytosol-to-membrane relocalization to bind and signal through the MAVS adaptor protein on intracellular membranes, thus directing downstream activation of IRF3 and innate immunity. Here, we report examination of the dynamic subcellular localization of all three RLRs within the intracellular response to dsRNA and RNA virus infection. Observations from high resolution biochemical fractionation and electron microscopy, coupled with analysis of protein interactions and IRF3 activation, show that, in resting cells, microsome but not mitochondrial fractions harbor the central components to initiate innate immune signaling. LGP2 interacts with MAVS in microsomes, blocking the RIG-I/MAVS interaction. Remarkably, in response to dsRNA treatment or RNA virus infection, LGP2 is rapidly released from MAVS and redistributed to mitochondria, temporally correlating with IRF3 activation. We reveal that IRF3 activation does not take place on mitochondria but instead occurs at endoplasmic reticulum (ER)-derived membranes. Our observations suggest ER-derived membranes as key RLR signaling platforms controlled through inhibitory actions of LGP2 binding to MAVS wherein LGP2 translocation to mitochondria releases MAVS inhibition to facilitate RLR-mediated signaling of innate immunity.

Entities:  

Keywords:  IRF3; LGP2; MAVS; RIG-I; innate immunity

Mesh:

Substances:

Year:  2020        PMID: 32571931      PMCID: PMC7354926          DOI: 10.1073/pnas.1921861117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

Review 1.  Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing.

Authors:  Qi Chen; Lijun Sun; Zhijian J Chen
Journal:  Nat Immunol       Date:  2016-09-20       Impact factor: 25.606

Review 2.  Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter.

Authors:  S Mehdi Belgnaoui; Suzanne Paz; John Hiscott
Journal:  Curr Opin Immunol       Date:  2011-08-22       Impact factor: 7.486

3.  Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3.

Authors:  M J Servant; B ten Oever; C LePage; L Conti; S Gessani; I Julkunen; R Lin; J Hiscott
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

4.  Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses.

Authors:  Thiagarajan Venkataraman; Maikel Valdes; Rachel Elsby; Shigeru Kakuta; Gisela Caceres; Shinobu Saijo; Yoichiro Iwakura; Glen N Barber
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

5.  Isolation of endoplasmic reticulum, mitochondria, and mitochondria-associated membrane fractions from transfected cells and from human cytomegalovirus-infected primary fibroblasts.

Authors:  Petros Bozidis; Chad D Williamson; Anamaris M Colberg-Poley
Journal:  Curr Protoc Cell Biol       Date:  2007-12

6.  Autoimmune disorders associated with gain of function of the intracellular sensor MDA5.

Authors:  Masahide Funabiki; Hiroki Kato; Yoshiki Miyachi; Hideaki Toki; Hiromi Motegi; Maki Inoue; Osamu Minowa; Aiko Yoshida; Katashi Deguchi; Hiroshi Sato; Sadayoshi Ito; Toshihiko Shiroishi; Kunio Takeyasu; Tetsuo Noda; Takashi Fujita
Journal:  Immunity       Date:  2014-02-13       Impact factor: 31.745

7.  ATP hydrolysis enhances RNA recognition and antiviral signal transduction by the innate immune sensor, laboratory of genetics and physiology 2 (LGP2).

Authors:  Annie M Bruns; Darja Pollpeter; Nastaran Hadizadeh; Sua Myong; John F Marko; Curt M Horvath
Journal:  J Biol Chem       Date:  2012-11-26       Impact factor: 5.157

8.  The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity.

Authors:  Jacquelyn A Gorman; Christian Hundhausen; John S Errett; Amy E Stone; Eric J Allenspach; Yan Ge; Tanvi Arkatkar; Courtnee Clough; Xuezhi Dai; Socheath Khim; Kathleen Pestal; Denny Liggitt; Karen Cerosaletti; Daniel B Stetson; Richard G James; Mohamed Oukka; Patrick Concannon; Michael Gale; Jane H Buckner; David J Rawlings
Journal:  Nat Immunol       Date:  2017-05-29       Impact factor: 25.606

Review 9.  Membranous replication factories induced by plus-strand RNA viruses.

Authors:  Inés Romero-Brey; Ralf Bartenschlager
Journal:  Viruses       Date:  2014-07-22       Impact factor: 5.048

10.  RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.

Authors:  Michael Ruzicka; Lars M Koenig; Simone Formisano; Daniel F R Boehmer; Binje Vick; Eva-M Heuer; Hanna Meinl; Lorenz Kocheise; Marcus Zeitlhöfler; Julia Ahlfeld; Sebastian Kobold; Stefan Endres; Marion Subklewe; Peter Duewell; Max Schnurr; Irmela Jeremias; Felix S Lichtenegger; Simon Rothenfusser
Journal:  Leukemia       Date:  2019-11-18       Impact factor: 11.528

View more
  20 in total

Review 1.  Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.

Authors:  Benjamin M Liu; Harry R Hill
Journal:  J Interferon Cytokine Res       Date:  2020-12       Impact factor: 2.607

2.  Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.

Authors:  Michael Brown
Journal:  Cancer Treat Res       Date:  2022

3.  Immune regulator LGP2 targets Ubc13/UBE2N to mediate widespread interference with K63 polyubiquitination and NF-κB activation.

Authors:  Jessica J Lenoir; Jean-Patrick Parisien; Curt M Horvath
Journal:  Cell Rep       Date:  2021-12-28       Impact factor: 9.423

4.  Mitochondrial antiviral-signalling protein is a client of the BAG6 protein quality control complex.

Authors:  Peristera Roboti; Craig Lawless; Stephen High
Journal:  J Cell Sci       Date:  2022-05-11       Impact factor: 5.235

Review 5.  Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors.

Authors:  Koji Onomoto; Kazuhide Onoguchi; Mitsutoshi Yoneyama
Journal:  Cell Mol Immunol       Date:  2021-01-18       Impact factor: 11.530

Review 6.  Inflammatory cytokine storms severity may be fueled by interactions of micronuclei and RNA viruses such as COVID-19 virus SARS-CoV-2. A hypothesis.

Authors:  Micheline Kirsch-Volders; Michael Fenech
Journal:  Mutat Res Rev Mutat Res       Date:  2021-09-28       Impact factor: 5.657

7.  TIAMMAt: Leveraging Biodiversity to Revise Protein Domain Models, Evidence from Innate Immunity.

Authors:  Michael G Tassia; Kyle T David; James P Townsend; Kenneth M Halanych
Journal:  Mol Biol Evol       Date:  2021-12-09       Impact factor: 16.240

8.  Analysis of Porcine RIG-I Like Receptors Revealed the Positive Regulation of RIG-I and MDA5 by LGP2.

Authors:  Shuangjie Li; Jie Yang; Yuanyuan Zhu; Hui Wang; Xingyu Ji; Jia Luo; Qi Shao; Yulin Xu; Xueliang Liu; Wanglong Zheng; François Meurens; Nanhua Chen; Jianzhong Zhu
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

9.  Bovine Delta Papillomavirus E5 Oncoprotein Interacts With TRIM25 and Hampers Antiviral Innate Immune Response Mediated by RIG-I-Like Receptors.

Authors:  Francesca De Falco; Anna Cutarelli; Ivan Gentile; Pellegrino Cerino; Valeria Uleri; Adriana Florinela Catoi; Sante Roperto
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  Human Norovirus NTPase Antagonizes Interferon-β Production by Interacting With IkB Kinase ε.

Authors:  Zifeng Zheng; Yuncheng Li; Mudan Zhang; Yalan Liu; Ming Fu; Sitang Gong; Qinxue Hu
Journal:  Front Microbiol       Date:  2021-07-15       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.